CSIMarket
 
Catalent Inc   (NYSE: CTLT)
Other Ticker:  
 
 
Price: $63.4800 $0.00 0.000%
Day's High: $63.5 Week Perf: 0.38 %
Day's Low: $ 63.43 30 Day Perf: 7.41 %
Volume (M): 13,629 52 Wk High: $ 63.50
Volume (M$): $ 865,180 52 Wk Avg: $58.18
Open: $63.49 52 Wk Low: $53.51



 Market Capitalization (Millions $) 11,534
 Shares Outstanding (Millions) 182
 Employees 16,900
 Revenues (TTM) (Millions $) 4,422
 Net Income (TTM) (Millions $) -413
 Cash Flow (TTM) (Millions $) 126
 Capital Exp. (TTM) (Millions $) 300

Catalent Inc
Catalent Inc. Overview

Catalent Inc. is a prominent global provider of advanced delivery technologies, development, and manufacturing solutions for a variety of healthcare products including pharmaceuticals, biologics, cell and gene therapies, and consumer health products. Founded in 2007 and headquartered in Somerset, New Jersey, the company has established a significant presence worldwide, operating over 35 facilities across North America, Europe, and the Asia-Pacific regions.

Core Services and Specialization

Catalent offers a comprehensive range of services centered around drug development and manufacturing, which include:

1. Drug Development: Catalent supports the drug development process from early-stage research to commercialization, focusing on optimizing formulations and improving clinical efficacy.

2. Clinical Trial Solutions: The company provides solutions to facilitate clinical trials, including the management and supply chain logistics necessary for global trials.

3. Analytical Testing: Catalent conducts extensive analytical testing services to ensure the quality and safety of products, which is crucial for regulatory compliance.

4. Drug Delivery Technologies: Catalent specializes in innovative delivery systems that enhance the bioavailability and performance of therapeutics, such as their proprietary delivery platforms that improve dosing precision and patient compliance.

5. Manufacturing Solutions: The company offers contract manufacturing services for a wide range of dosage forms including softgels, tablets, and injectable formulations, ensuring that products meet the high standards required by the industry.

Business Segments

Catalent operates through four distinct business segments:

1. Softgel and Oral Technologies: This segment focuses on the development and manufacture of a diverse array of solid and semi-solid dosage forms, particularly softgel capsules, which are known for their enhanced bioavailability and patient compliance.

2. Biologics: Catalents Biologics segment provides comprehensive services for gene therapy and biomanufacturing, offering expertise to biotechnology companies that develop complex biologic therapies.

3. Oral and Specialty Delivery: This segment is dedicated to the creation of advanced delivery technologies aimed at improving the effectiveness and stability of oral dosage forms. The OptiDose system developed by Catalent is a notable innovation, allowing for uniform granulation and efficient tablet compaction.

4. Clinical Supply Services: Catalent ensures that clinical trial supply chains function seamlessly, providing crucial support to facilitate the distribution and management of drugs during trials.

Commitment to Sustainability

Catalent is dedicated to sustainability and employs environmentally responsible practices across its operations. The company works with clients to integrate greener manufacturing processes, utilizing eco-friendly materials and technologies aimed at reducing energy use and minimizing waste. Catalent also engages in partnerships with academic institutions and industry leaders to promote improved health outcomes globally.

Conclusion

Catalent Inc. stands out as a key player in the pharmaceutical and biotechnology sectors, renowned for its advanced drug development and delivery systems. The company operates with a commitment to innovation, quality, and efficiency, helping clients ranging from large pharmaceutical firms to smaller biotech companies navigate the complexities of bringing life-changing treatments to market. With its global footprint and focus on sustainable practices, Catalent continues to shape the future of drug development and manufacturing.


   Company Address: 14 Schoolhouse Road Somerset, 8873 NJ
   Company Phone Number: 537-6200   Stock Exchange / Ticker: NYSE CTLT


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
CDMO        0.4% 
CORT        3.1% 
CYRX   -3.71%    
ATR   -9.43%    
CRL   -5.87%    
TKNO   -12.69%    
• View Complete Report
   



Business Update

Catalents $25 Million Expansion Elevates European Clinical Supply Expertise in Schorndorf

Published Tue, Jul 16 2024 7:47 AM UTC

Catalent s $25 Million Expansion Elevates European Clinical Supply Expertise in Schorndorf Catalent, Inc. (NYSE: CTLT), a global leader in enabling the development and supply of better treatments for patients worldwide, proudly announces the completion of a significant expansion of its clinical supply facility located in Schorndorf, Germany. This state-of-the-art facility, C...

Catalent Inc

Catalent Inc. Reports Substantial Revenue Growth of 3.568% in Fiscal Q3 2024

Financial News Report: Catalent Inc Shows Positive Growth in Q3 2024
Catalent Inc (NYSE: CTLT) has reported positive financial results for the third quarter of 2024, with a decrease in loss per share and an increase in revenue. The company's progress has been highlighted through its outperformance of industry contemporaries and its commitment to corporate responsibility.
In terms of financial performance, CTLT decreased its loss per share to $-0.56, compared to $-1.26 in the same quarter a year prior. Additionally, EPS improved from $-1.13 in the previous reporting season. The revenue also saw growth, increasing by 3.568% to $1.07 billion from $1.04 billion in the corresponding reporting season a year prior. Sequentially, the revenue advanced by 4.883% from $1.02 billion.

Product Service News

Catalent's Commitment to Corporate Responsibility: Progress, Initiatives, and Future Commitments

Published Thu, Mar 7 2024 1:00 PM UTC

Catalent, Inc. (NYSE: CTLT), the global leader in facilitating the development and supply of innovative treatments for patients worldwide, has recently released its fifth annual Corporate Responsibility Report for fiscal year 2023. This report showcases the significant progress the company has made across its three core pillars of corporate responsibility, namely People, Env...

Catalent Inc

Catalent Inc's Disappointing Performance: Unveiling the Culprits Behind Weak Sales in the Tragic December 2023 Quarter

Catalent Inc is a leading player in the pharmaceutical industry, specializing in the development and supply of advanced treatments for patients worldwide. Their recent financial results for the fiscal time-frame ending December 31, 2023, may have raised some concerns due to diminishing returns and a decrease in revenue. However, it is important to note that the company also reported an improvement in EPS and sequential revenue growth, showing that there is still momentum and potential for growth.
Despite the challenges faced by Catalent Inc in the past reporting season, the overall Major Pharmaceutical Preparations sector recorded a revenue growth of 3.59% in the second quarter of 2024. This indicates that the industry as a whole is still performing well, which could potentially benefit Catalent Inc in the long run.

Merger and Acquisition

Novo Holdings to Acquire Catalent: A Landmark Merger in the Pharmaceutical Industry

Published Mon, Feb 5 2024 11:00 AM UTC


In a recent press release, Catalent Inc. (NYSE: CTLT), a globally renowned company specializing in developing and supplying advanced treatments for patients worldwide, and Novo Holdings, a leading investment firm responsible for managing the assets and wealth of the Novo Nordisk Foundation, revealed their plans for a significant merger. Under this merger agreement, Novo...







Catalent Inc's Segments
Excluding InterElimination    100.1 % of total Revenue
Biologics    45.06 % of total Revenue
PharmaConsumerHealth    55.03 % of total Revenue
Total Catalent InterEliminations    -0.1 % of total Revenue
United States    64.32 % of total Revenue
Europe    32.36 % of total Revenue
International Other    6.65 % of total Revenue
Biologics Manufacturing Commercial Product Supply    23.85 % of total Revenue
Biologics Development Services    21.21 % of total Revenue
PharmaConsumerHealth Manufacturing Commercial Product Supply    35.39 % of total Revenue
PharmaConsumerHealth Development Services    19.65 % of total Revenue
Total Catalent before inter-revenue elimination Manufacturing Commercial Product Supply    59.24 % of total Revenue
Total Catalent before inter-revenue elimination Development Services    40.86 % of total Revenue





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2025 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com